Company news
Nuformix Plc (LSE:NFX) news
Nuformix Plc news releases on 6ix. Latest, Aug 25, 2026: Appointment of Chairman
Press releases & updates
Appointment of Chairman
August 25, 2026
NXP002 Development Update
August 19, 2026
Half Year Report
May 28, 2026
Total Voting Rights
March 31, 2026
£1.0 million Placing
March 11, 2026
Confirmation of US ODD for NXP002 in IPF
March 10, 2026
Result of AGM
March 3, 2026
Posting of Annual Report and Notice of AGM
February 5, 2026
Annual Results for period ended 30 September 2025
January 27, 2026
Update re. US FDA ODD Application
November 12, 2025
Underwritten Open Offer
October 28, 2025
Change of Auditor
October 10, 2025
European Respiratory Society Congress Attendance
September 25, 2025
US FDA ODD Application Submitted for NXP002
August 11, 2025
Confirmation of European ODD for NXP002
May 29, 2025
Publication of a Prospectus
May 23, 2025
£210,000 Placing
May 22, 2025
Attendance at American Thoracic Society Congress
May 19, 2025
Half-year Report
May 2, 2025
Confirmation of European Orphan Drug Designation
April 30, 2025
Change of Registered Office and Company Secretary
April 29, 2025
Correction - Exercise of Warrants
April 14, 2025
NXP002 Update
April 9, 2025
£168,750 Placing
January 30, 2025
Annual Results for period ended 30 September 2024
January 29, 2025
NXP002 ODD Application Submitted
January 28, 2025
NXP002 Orphan Drug Designation Draft Application
January 13, 2025
Director/PDMR Dealings
November 5, 2024
Result of General Meeting
November 4, 2024
Publication of Prospectus & Notice of GM
October 16, 2024
£300,000 Fundraise
September 20, 2024
Patent Update
June 17, 2024
Subscription to raise £150,000
March 1, 2024
Results for the period ended 30 September 2023
January 3, 2024
NXP001 Update
December 18, 2023
Notice of Allowance of NXP002 Patent in Japan
October 23, 2023
Nuformix to fund its unlicensed programs with NXP001 windfall
October 5, 2023
Result of Annual General Meeting
August 24, 2023
Notice of AGM
July 31, 2023
Holding(s) in Company
July 26, 2023
Investor Online Q&A
June 2, 2023
Unaudited Interim Report
May 22, 2023
NXP002 Inflammation and Duration of Action Update
May 18, 2023
Subscription to raise £70,000 & issue of Warrants
April 17, 2023
Change of Accounting Reference Date
March 13, 2023
Nuformix hoping to 'initiate discussions with m...
December 20, 2022
Resignation of Auditor
December 5, 2022
Investor Webinar
November 4, 2022
NXP002 Completion of Tolerability Studies
August 10, 2022
Board Changes
July 28, 2022